The patent expiry of the blockbuster drug semaglutide, used for type 2 diabetes and weight management, is projected to create a generic market opportunity of approximately ₹5,000 crore. Indian pharmaceutical firms, alongside global manufacturers, are expected to share this market. Companies like Sun Pharma, Dr Reddy's, and Cipla are identified as potential beneficiaries. The Indian market is anticipated to see an incremental revenue of ₹1,000-2,000 crore in FY27 following generic entry in March 2026.